Le Lézard
Classified in: Health, Science and technology, Business
Subjects: FNC, VEN

J2 Health Raises $4.5 Million in Seed Funding


NEW YORK, March 14, 2022 /PRNewswire/ -- J2 Health ? a B2B healthcare SaaS company ? has raised a $4.5 million Seed investment round, led by New York-based venture capital firms Primary Ventures, Tiger Global and BoxGroup to enable healthcare organizations to optimize provider network performance. Industry leaders including Mario Schlosser, CEO of Oscar Health, also participated in the round.

Most Americans access healthcare through a provider network - the doctors and hospitals contracted with health insurers to deliver care. Insurers, however, struggle to build the best networks for their customers, relying on complex, unreliable data and disjointed processes. 

"Even the most sophisticated organizations struggle with foundational questions, like who are the doctors we are contracted with," says CEO Josh Poretz, who has deep experience constructing provider networks. "The complex questions we need to answer to improve healthcare ? are our networks good, how can we deliver more value to consumers ? are severely underserved."

J2 Health, whose name was inspired by the Portuguese word "jeito" meaning "the way", provides just that: a systematic way of evaluating network quality and identifying improvements. Its intuitive interface and advanced analytics help organizations streamline the path to high performing networks, making strategic network design and management easy. 

Founded in April 2020, J2 seeks to capitalize on significant early momentum by fueling product development, expanding its data and analytics offerings and growing its team. 

To explore further please visit www.j2health.com

Media Contact
[email protected]

SOURCE J2 Health


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: